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A new growth 
hormone–releasing  
factor agonist improves 
uremic cachexia
Cachexia is one of the hallmarks of end-
stage renal disease, its presence a harbinger 
of a poor outcome. Often, this condition is 
associated with insulin and growth hor-
mone resistance. As they report in this 
issue, Niemczyk et al. administered a new 
growth hormone−releasing hormone 
‘super-agonist’ (AKL-0707) to patients 
with advanced chronic kidney disease. 
They found that the treatment increased 
growth hormone secretion fourfold after 28 
days, without altering the characteristics of 
pulsatile growth hormone release. The treat-
ment also doubled the serum insulin-like 
growth factor-1 level. Subjective assessment 
of the patients showed that most of them 
looked better nourished. By dual-energy 
X-ray absorptiometry, the mean fat-free 
mass and body mineral content increased, 
while fat mass decreased. Studies of nitro-
gen metabolism suggested that the patients 
were in a positive nitrogen balance. These 
studies offer a new avenue of treatment for 
uremic cachexia. See page 450.
Dimethylarginine and 
progression of CKD
Asymmetric dimethylarginine is an endog-
enous nitric oxide synthase inhibitor whose 
level is often elevated in chronic kidney dis-
ease (CKD); it may be involved in the pro-
gressive decline in glomerular filtration rate 
(GFR) so often seen in CKD. As they report 
in this issue, Caplin et al. studied polymor-
phisms in the two enzymes responsible for 
degrading dimethylarginine, DDAH1 and 
DDAH2. They found that one genotype 
(rs17384213 DDAH1 GG) was associated 
with increased expression of its mRNA in 
kidney allografts. Healthy subjects carry-
ing the same genotype had lower plasma 
asymmetric dimethylarginine. Similarly, 
the same weak association was found in 
a cohort of CKD. However, this allele was 
associated with a steeper decline in renal 
function in two separate cohorts of patients 
with CKD. The interesting finding is that 
while this polymorphism contributes to the 
decline in GFR, it seems that increases in 
circulating methylarginine did not mediate 
progressive kidney injury. See page 459.
Verapamil blocks 
vascular calcification
Vascular calcification in end-stage renal 
disease has emerged as one of the most 
significant complications of this condi-
tion. L-type calcium channels are present 
in vascular smooth muscle and are likely 
to be intimately involved in the genera-
tion of the calcification. Chen et al. exam-
ined whether blockade of these channels 
by verapamil could ameliorate the calci-
fication. Using bovine vascular smooth 
muscle cells or rat aorta incubated in 
calcifying media, the authors found 
that verapamil reduced the calcification 
whereas dihydropyridine drugs did not. 
Verapamil reduced alkaline phosphatase 
activity of bovine vascular smooth muscle 
cells. It also inhibited matrix vesicle alka-
line phosphatase activity and reduced the 
ability of these matrix vesicles to subse-
quently calcify on a type I collagen extra-
cellular matrix scaffold. These large effects 
suggest that verapamil inhibits calcifica-
tion. However, the finding that nifedipine 
and nimodipine—two dihydropyridine 
drugs that are potent blockers of L-type 
calcium channels—had no effect suggests 
that the target of verapamil, in this case, 
is some calcium transport protein yet to 
be identified. See page 436.
It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
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